These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 16642045)

  • 1. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.
    Martelli AM; Nyåkern M; Tabellini G; Bortul R; Tazzari PL; Evangelisti C; Cocco L
    Leukemia; 2006 Jun; 20(6):911-28. PubMed ID: 16642045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway.
    Doepfner KT; Spertini O; Arcaro A
    Leukemia; 2007 Sep; 21(9):1921-30. PubMed ID: 17581609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
    Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
    Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
    Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.
    Papa V; Tazzari PL; Chiarini F; Cappellini A; Ricci F; Billi AM; Evangelisti C; Ottaviani E; Martinelli G; Testoni N; McCubrey JA; Martelli AM
    Leukemia; 2008 Jan; 22(1):147-60. PubMed ID: 17928881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K-Akt pathway: its functions and alterations in human cancer.
    Osaki M; Oshimura M; Ito H
    Apoptosis; 2004 Nov; 9(6):667-76. PubMed ID: 15505410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of LanthaScreen cellular assays for key components within the PI3K/AKT/mTOR pathway.
    Carlson CB; Robers MB; Vogel KW; Machleidt T
    J Biomol Screen; 2009 Feb; 14(2):121-32. PubMed ID: 19196698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers.
    Michl P; Downward J
    Z Gastroenterol; 2005 Oct; 43(10):1133-9. PubMed ID: 16220453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways.
    Choi JA; Park MT; Kang CM; Um HD; Bae S; Lee KH; Kim TH; Kim JH; Cho CK; Lee YS; Chung HY; Lee SJ
    Oncogene; 2004 Jan; 23(1):9-20. PubMed ID: 14712206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.
    Martelli AM; Lonetti A; Buontempo F; Ricci F; Tazzari PL; Evangelisti C; Bressanin D; Cappellini A; Orsini E; Chiarini F
    Adv Biol Regul; 2014 Sep; 56():6-21. PubMed ID: 24819383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the PI3K-AKT pathway in melanoma.
    Davies MA
    Cancer J; 2012; 18(2):142-7. PubMed ID: 22453015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts.
    Tazzari PL; Cappellini A; Ricci F; Evangelisti C; Papa V; Grafone T; Martinelli G; Conte R; Cocco L; McCubrey JA; Martelli AM
    Leukemia; 2007 Mar; 21(3):427-38. PubMed ID: 17215852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target of rapamycin signaling in leukemia and lymphoma.
    Vu C; Fruman DA
    Clin Cancer Res; 2010 Nov; 16(22):5374-80. PubMed ID: 20826559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PI3K inhibitor].
    Yano S; Takeuchi S; Yamada T; Mouri H; Yamashita K; Ohtsubo K; Yasumoto K
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):23-6. PubMed ID: 21368457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
    Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
    Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
    Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The PI3K/Akt/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia].
    Dos Santos C; Récher C; Demur C; Payrastre B
    Bull Cancer; 2006 May; 93(5):445-7. PubMed ID: 16777621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BacMam-enabled LanthaScreen cellular assays for PI3K/Akt pathway compound profiling in disease-relevant cell backgrounds.
    Carlson CB; Mashock MJ; Bi K
    J Biomol Screen; 2010 Mar; 15(3):327-34. PubMed ID: 20145103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
    Zhou Q; Lui VW; Yeo W
    Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer.
    Goc A; Al-Husein B; Kochuparambil ST; Liu J; Heston WW; Somanath PR
    Int J Oncol; 2011 Jan; 38(1):267-77. PubMed ID: 21109949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.